International Assets Investment Management LLC Buys Shares of 12,191 Bio-Techne Co. (NASDAQ:TECH)

International Assets Investment Management LLC purchased a new stake in Bio-Techne Co. (NASDAQ:TECH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,191 shares of the biotechnology company's stock, valued at approximately $941,000.

• Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points

A number of other hedge funds also recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Bio-Techne in the 3rd quarter valued at approximately $27,000. CVA Family Office LLC bought a new stake in shares of Bio-Techne during the fourth quarter valued at about $31,000. Federated Hermes Inc. acquired a new stake in Bio-Techne in the third quarter worth about $47,000. Clear Street Markets LLC grew its position in Bio-Techne by 255.8% in the 3rd quarter. Clear Street Markets LLC now owns 733 shares of the biotechnology company's stock valued at $50,000 after buying an additional 527 shares in the last quarter. Finally, Global Retirement Partners LLC increased its stake in Bio-Techne by 17.3% during the 3rd quarter. Global Retirement Partners LLC now owns 1,514 shares of the biotechnology company's stock valued at $101,000 after buying an additional 223 shares during the period. Institutional investors own 98.95% of the company's stock.

Insiders Place Their Bets

In other news, Director Roeland Nusse sold 10,400 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $76.98, for a total value of $800,592.00. Following the completion of the sale, the director now directly owns 43,097 shares of the company's stock, valued at $3,317,607.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.10% of the company's stock.

Bio-Techne Stock Performance

Shares of TECH opened at $62.80 on Tuesday. The company has a 50-day moving average of $70.35 and a two-hundred day moving average of $68.61. The stock has a market cap of $9.87 billion, a price-to-earnings ratio of 45.51, a PEG ratio of 7.73 and a beta of 1.22. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.37 and a quick ratio of 3.03. Bio-Techne Co. has a one year low of $51.79 and a one year high of $89.91.

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its quarterly earnings data on Thursday, February 1st. The biotechnology company reported $0.33 EPS for the quarter, missing analysts' consensus estimates of $0.36 by ($0.03). Bio-Techne had a return on equity of 14.21% and a net margin of 19.58%. The firm had revenue of $272.60 million during the quarter, compared to analyst estimates of $277.48 million. On average, equities research analysts expect that Bio-Techne Co. will post 1.52 earnings per share for the current year.

Bio-Techne Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 26th. Investors of record on Monday, February 12th were paid a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend was Friday, February 9th. Bio-Techne's dividend payout ratio is currently 23.19%.

Analysts Set New Price Targets

Several research firms have recently issued reports on TECH. Stephens decreased their price objective on shares of Bio-Techne from $92.00 to $87.00 and set an "overweight" rating for the company in a report on Friday, February 2nd. Royal Bank of Canada lowered their price target on Bio-Techne from $85.00 to $75.00 and set a "sector perform" rating on the stock in a research report on Friday, February 2nd. Scotiabank began coverage on Bio-Techne in a report on Thursday, February 8th. They issued a "sector outperform" rating and a $80.00 price objective for the company. Deutsche Bank Aktiengesellschaft lowered their target price on Bio-Techne from $85.00 to $82.00 and set a "buy" rating on the stock in a report on Thursday, April 18th. Finally, Stifel Nicolaus downgraded shares of Bio-Techne from a "buy" rating to a "hold" rating and set a $65.00 price target for the company. in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $83.90.

Read Our Latest Stock Analysis on Bio-Techne

Bio-Techne Company Profile

(Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

Read More

• Five stocks we like better than Bio-Techne
• Using the MarketBeat Stock Split Calculator
• It’s Time to Buy Into the Super Micro Computer Stock Implosion
• How to Calculate Return on Investment (ROI)
• Merger or Not, Albertson’s Companies is a Good Buy
• How is Compound Interest Calculated?
• 3 Cheap Stocks That Shouldn’t Be So

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Co. (NASDAQ:TECH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad)

Should you invest $1,000 in Bio-Techne right now?

Before you consider Bio-Techne, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.

While Bio-Techne currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here